INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,751,864 | -11.1% | 453,883 | -1.0% | 0.01% | -10.0% |
| Q2 2023 | $30,081,708 | +21.7% | 458,353 | -0.6% | 0.01% | -9.1% |
| Q4 2022 | $24,721,068 | +14.4% | 461,300 | -0.1% | 0.01% | +22.2% |
| Q3 2022 | $21,605,000 | -19.5% | 461,731 | +0.2% | 0.01% | -25.0% |
| Q2 2022 | $26,824,000 | -5.1% | 460,669 | -1.4% | 0.01% | -14.3% |
| Q1 2022 | $28,278,000 | +83.1% | 467,397 | +61.7% | 0.01% | +75.0% |
| Q4 2021 | $15,443,000 | +42.8% | 288,977 | +0.1% | 0.01% | +60.0% |
| Q3 2021 | $10,812,000 | -7.1% | 288,704 | -0.1% | 0.01% | -16.7% |
| Q2 2021 | $11,640,000 | +65.1% | 288,849 | +29.1% | 0.01% | +20.0% |
| Q1 2021 | $7,049,000 | +7.4% | 223,708 | +9.2% | 0.01% | +25.0% |
| Q4 2020 | $6,561,000 | +28.5% | 204,897 | +3.7% | 0.00% | 0.0% |
| Q3 2020 | $5,107,000 | +813.6% | 197,635 | +763.6% | 0.00% | +300.0% |
| Q2 2020 | $559,000 | +110.2% | 22,884 | +24.0% | 0.00% | – |
| Q1 2020 | $266,000 | -40.0% | 18,453 | +43.3% | 0.00% | – |
| Q4 2019 | $443,000 | +906.8% | 12,875 | +118.0% | 0.00% | – |
| Q3 2019 | $44,000 | -52.2% | 5,906 | -16.4% | 0.00% | – |
| Q2 2019 | $92,000 | +130.0% | 7,067 | +114.4% | 0.00% | – |
| Q1 2019 | $40,000 | -37.5% | 3,296 | -40.9% | 0.00% | – |
| Q4 2018 | $64,000 | -47.5% | 5,578 | -1.0% | 0.00% | – |
| Q3 2018 | $122,000 | +22.0% | 5,633 | -0.2% | 0.00% | – |
| Q2 2018 | $100,000 | -10.7% | 5,642 | +6.0% | 0.00% | – |
| Q1 2018 | $112,000 | +23.1% | 5,324 | -15.8% | 0.00% | – |
| Q4 2017 | $91,000 | -8.1% | 6,324 | 0.0% | 0.00% | – |
| Q3 2017 | $99,000 | +23.8% | 6,324 | -2.3% | 0.00% | – |
| Q2 2017 | $80,000 | -83.1% | 6,476 | -77.7% | 0.00% | – |
| Q1 2017 | $473,000 | +827.5% | 29,105 | +699.4% | 0.00% | – |
| Q4 2016 | $51,000 | -81.7% | 3,641 | -80.0% | 0.00% | – |
| Q3 2016 | $278,000 | +79.4% | 18,172 | +354.3% | 0.00% | – |
| Q2 2016 | $155,000 | +39.6% | 4,000 | 0.0% | 0.00% | – |
| Q1 2016 | $111,000 | +3600.0% | 4,000 | +6566.7% | 0.00% | – |
| Q4 2015 | $3,000 | -97.5% | 60 | -98.0% | 0.00% | – |
| Q3 2015 | $120,000 | – | 3,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |